BRIEF: Simcere Pharma profit surges in 2025
Innovative drugmaker Simcere Pharmaceutical Group Ltd. (2096.HK) said on Wednesday it expects to report a 2025 profit of between 1.3 billion yuan ($189 million) and 1.4 billion yuan, up 80.1%…
INDUSTRY BRIEF: Healthcare stocks under pressure as national drug list expands
Many Hong Kong-listed drugmakers on Monday announced their products that were included in the 2025 edition of China’s National Reimbursement Drug List (NRDL), which was unveiled this week. The updated…
Will new investor Goldstream bring its Midas touch to Saint Bella?
The investment company disclosed its purchase of 0.3% of the maternity and baby care company’s stock on the open market Key Takeaways: Goldstream Investment acquired 1.83 million Saint Bella shares,…
FAST NEWS: Simcere Pharma Surges After Applying for New Drug Clinical Trials
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) said on Thursday its self-developed anti-tumor drug candidates SIM0237 and SIM0348 were accepted by the Center For Drug Evaluation of China’s National Medical…
FAST NEWS: Investment Loss Undermines Simcere Pharma’s Profit
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) on Wednesday reported its revenue grew 27.3% to 2.7 billion yuan ($389 million) in the first half of the year, while its net profit…
FAST NEWS: Simcere Pharma Says 2021 Profit Doubled, But Shares Fall
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) released a positive profit alert on Monday evening, estimating its net profit last year was in the range of 1.48 billion ($233 million)…
Recent Articles
RELATED ARTICLES
-
Its accounting scandal wrapping up, Lufax faces bigger challenge from China’s economy
- Big deal, bigger doubts: CSPC slides after $18.5 billion pact
- China’s biopharma sector enters the New Year on a high
-
Joinn’s ‘jumping’ monkey market hides core weakness
6127.HK603127.SHG
- BRIEF: China Resources Building Materials profit doubles in 2025
